Last reviewed · How we verify
ASP7962
ASP7962 is a small molecule inhibitor of the PI3K delta subunit.
ASP7962 is a small molecule inhibitor of the PI3K delta subunit. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | ASP7962 |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Drug class | PI3K delta inhibitor |
| Target | PI3K delta |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting the PI3K delta subunit, ASP7962 is thought to modulate immune cell function and potentially treat various immune-related disorders.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Nausea
- Diarrhea
- Headache
Key clinical trials
- A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee (PHASE2)
- A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects (PHASE1)
- A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ASP7962 CI brief — competitive landscape report
- ASP7962 updates RSS · CI watch RSS
- Astellas Pharma Europe B.V. portfolio CI